Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2612625 | 0.77 | ALDH1A1 (0.36) | ALDH1A1HTR4CHRM1SLC6A2SLC6A4 | |
| SCHEMBL12404066 | 0.77 | LMNA (0.44) | HTR4CHRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14388282 | 0.75 | KCNH2 (0.38) | ALDH1A1HTR4CHRM1SLC6A2SLC6A4 | |
| SCHEMBL20043249 | 0.75 | — | — | |
| SCHEMBL2887259 | 0.75 | — | — | |
| SCHEMBL14418085 | 0.72 | HSD11B1 (0.33) | — | |
| SCHEMBL18199672 | 0.72 | HSD11B1 (0.33) | — | |
| SCHEMBL25518308 | 0.72 | CHRM1 (0.39) | ALDH1A1HTR4CHRM1SLC6A2SLC6A4 | |
| SCHEMBL21739053 | 0.71 | KMT2A (0.57) | ALDH1A1HTR4CHRM1 | |
| SCHEMBL20805544 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | ALDH1A1 1577/4885CACNA1H 4092/4885HTR4 1536/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | ALDH1A1 1577/4885CACNA1H 4092/4885HTR4 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.